Latest Earnings Released (Q1 FY27): Reported quarterly statutory revenue of ₹230.39 Cr with net profit of ₹47.01 Cr (EPS: ₹7.49).
Exchange Disclosure (2026-10-28): Analysts/Institutional Investor Meet/Con. Call Updates —
Official listing profile for Symbiotec Pharmalab Limited under Diversified.
Official listing profile for Symbiotec Pharmalab Limited under Diversified.
Commercial & Industrial
Score Under Review
Fundamental Health Score calculation requires a minimum of two consecutive audited annual financial filings. This corporation profile is currently awaiting complete verified financial history before generating an algorithmic score.
| Annual Metric (₹ Cr) | FY26 Mar 2026 |
|---|---|
| Sales / Revenue from Operations | ₹211 |
| Operating Expenditure | ₹152 |
| Operating Profit (EBITDA) | ₹59 |
| Operating Profit Margin (OPM %) | 28.10% |
| Other Income | ₹20 |
| Finance Costs / Interest | ₹5.62 |
| Depreciation & Amortization | ₹10 |
| Profit Before Tax (PBT) | ₹63 |
| Tax Expense | ₹16 |
| Net Profit (PAT) | ₹47 |
| Net Profit Margin (NPM %) | 22.30% |
| Basic / Diluted EPS (₹) | ₹7.49 |
| Quarterly Metric (₹ Cr) | Q1 FY27 Jun 2026 |
|---|---|
| Sales / Revenue | ₹230 |
| Operating Profit (EBITDA) | ₹63 |
| OPM % | 27.35% |
| Profit Before Tax (PBT) | ₹63 |
| Net Profit (PAT) | ₹47 |
| NPM % | 20.40% |
| Basic / Diluted EPS (₹) | ₹7.49 |
| Balance Sheet Item (₹ Cr) | FY26 |
|---|---|
| Equity Share Capital | ₹13 |
| Reserves & Surplus | N/A |
| Net Worth (Shareholders' Funds) | ₹13 |
| Total Borrowings & Debt | N/A |
| Total Balance Sheet Assets | N/A |
| Cash Flow Item (₹ Cr) | FY26 |
|---|---|
| Cash Flow from Operating Activities (CFO) | N/A |
| Cash Flow from Investing Activities (CFI) | N/A |
| Cash Flow from Financing Activities (CFF) | N/A |
| Free Cash Flow / Net Cash Flow | N/A |
| Financial Ratio / Efficiency Metric | FY26 |
|---|---|
| Operating Profit Margin (OPM) | 28.10% |
| Net Profit Margin (NPM) | 22.30% |
| Return on Equity (ROE) | 374.58% |
| Return on Capital Employed (ROCE) | 546.93% |
| Debt to Equity Ratio | N/A |
| Interest Coverage Ratio | 10.5x |
Verified Statutory Auditor per SEBI Integrated Financial Disclosure.
| Type | Ex-Date | Record Date | Amount / Ratio | Description |
|---|---|---|---|---|
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹2.00 | Final Dividend - Rs. - 2.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹7.00 | Final Dividend - Rs. - 7.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.50 | Final Dividend - Rs. - 0.5000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹5.00 | Final Dividend - Rs. - 5.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.55 | Final Dividend - Rs. - 0.5500 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹25.00 | Final Dividend - Rs. - 25.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹3.00 | Final Dividend - Rs. - 3.0000 |
| CORPORATE_ACTION | 2026-09-15 | 2026-09-15 | N/A | Right Issue of Equity Shares |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹1.00 | Final Dividend - Rs. - 1.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.30 | Final Dividend - Rs. - 0.3000 |
Symbiotec Pharmalab Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical company forDual Chamber Vial ('DCV') products in the U.S.
General Updates
Symbiotec Pharmalab Limited has informed the Exchange about General Updates
General Updates
Symbiotec Pharmalab Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Symbiotec Pharmalab Limited has informed the Exchange about General Updates
Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical company forDual Chamber Vial ('DCV') products in the U.S.
Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report ("EIR") From U.S. FDA for Its Manufacturing Facility In Pithampur ('SEZ') With VAI Classification
Symbiotec Pharmalab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Symbiotec Pharmalab Limited has informed the Exchange about Transcript
Every financial metric, balance-sheet balance, and shareholding breakdown displayed on this dossier is grounded in primary statutory filings submitted to Indian stock exchanges (SEBI LODR Regulations 31, 33, and 47). No data is manufactured, estimated, or interpolated.
| Data Domain | Reporting Period | Statutory Source | Ingestion Date | Status | Provenance Hash |
|---|---|---|---|---|---|
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 04 Nov 2026, 14:16 | VERIFIED | 28d811da60d4... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 01 Nov 2026, 18:39 | VERIFIED | 28d811da60d4... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 29 Oct 2026, 11:20 | VERIFIED | 28d811da60d4... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 26 Oct 2026, 23:45 | VERIFIED | 6e1fa9ad0faa... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 23 Oct 2026, 14:46 | VERIFIED | 6e1fa9ad0faa... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 19 Oct 2026, 04:45 | VERIFIED | 6e1fa9ad0faa... |
| financials_quarterly | Q1 FY27 | NSE_OFFICIAL_API | 14 Oct 2026, 21:45 | VERIFIED | f8e48de0bc85... |
DATA SOURCES, STATUTORY DISCLOSURES & METHODOLOGY
All corporate identifiers, listed equity data, shareholding patterns, and financial statements are extracted from official regulatory authorities: National Stock Exchange of India (NSE), BSE Limited, and Ministry of Corporate Affairs (MCA) via audited XBRL Ind-AS submissions under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations 31, 33, and 47). Data is ingested and archived on official end-of-day (EOD) schedules with immutable provenance tracking.
Zero-Fabrication Policy: SRK Money Talk strictly enforces authentic data integrity. No financial values, debt levels, cash flows, or quarterly earnings are ever mathematically synthesized, interpolated, or fabricated. When statutory disclosures have not yet been filed or ingested, fields are strictly labeled as N/A or NOT_YET_AVAILABLE.
Statutory Disclaimer: The SRK Fundamental Health Score is a quantitative diagnostic algorithm based exclusively on historical audited filings and does not constitute an investment recommendation or financial advisory. Always consult a SEBI-registered investment adviser before making capital allocation decisions.